10,592 results match your criteria Acute Promyelocytic Leukemia


Early treatment of acute promyelocytic leukaemia is accurately guided by the PML protein localisation pattern: real-life experience from a tertiary New Zealand centre.

Pathology 2019 Mar 12. Epub 2019 Mar 12.

Department of Pathology and Laboratory Medicine, LabPlus, Auckland City Hospital, Auckland, New Zealand; Department of Molecular Medicine and Pathology, School of Medical Sciences, University of Auckland, Auckland, New Zealand. Electronic address:

Current guidelines recommend that a rapid test be used to assist diagnosis of acute promyelocytic leukaemia (APL), but the choice of an assay is discretionary. PML immunofluorescence (PML IF) identifies the microparticulate pattern of the PML protein localisation, highly specific for APL. The aim of this study was to evaluate clinical utility of PML IF in a real-life setting based on a retrospective records review for all patients who had PML IF performed in our centre between 2000 and 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pathol.2019.01.003DOI Listing

Phenylarsine Oxide Can Induce Degradation of PLZF-RARα Variant Fusion Protein of Acute Promyelocytic Leukemia.

Chem Res Toxicol 2019 Mar 15. Epub 2019 Mar 15.

Inner Mongolia Medical University , Huhot , China.

PLZF-RARα is the second most frequent variant acute promyelocytic leukemia (APL) fusion protein that ranks after PML-RARα in APL. However, PLZF-RARα is resistant to current front line APL treatments including all transretinoic acid (ATRA), arsenic trioxide (ATO), and chemotherapy (i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.chemrestox.9b00072DOI Listing
March 2019
3.529 Impact Factor

Comparative transcriptome analyses revealed differential strategies of roots and leaves from methyl jasmonate treatment Baphicacanthus cusia (Nees) Bremek and differentially expressed genes involved in tryptophan biosynthesis.

PLoS One 2019 13;14(3):e0212863. Epub 2019 Mar 13.

School of Life science, Fujian Agriculture and Forestry University, Fuzhou, Fujian, China.

Baphicacanthus cusia (Nees) Bremek (B. cusia) is an effective herb for the treatment of acute promyelocytic leukemia and psoriasis in traditional Chinese medicine. Methyl jasmonate (MeJA) is a well-known signaling phytohormone that triggers gene expression in secondary metabolism. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0212863PLOS
March 2019
1 Read

Identification of chromosomal abnormalities and genomic features in near-triploidy/tetraploidy-acute leukemia by fluorescence in situ hybridization.

Cancer Manag Res 2019 15;11:1559-1567. Epub 2019 Feb 15.

Department of Clinical Laboratory, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China,

Background: Near-triploidy/tetraploidy is rarely found in acute leukemia. Only limited data are available to characterize this condition, and it remains largely unknown.

Patients And Methods: In our study, we performed karyotype analysis on 1,031 patients diagnosed with acute leukemia from 2006 to 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S189025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388942PMC
February 2019
2 Reads

Unilateral serous retinal detachment with choroidal thickening as a first presenting sign of acute myeloid leukemia.

Am J Ophthalmol Case Rep 2019 Jun 23;14:51-54. Epub 2019 Feb 23.

Department of Ophthalmology and Visual Science, Kochi Medical School, Kochi University, Nankoku City, Kochi, Japan.

Purpose: Serous retinal detachment is rare in leukemia, but bilateral or unilateral cases have been reported as the presenting sign of acute leukemia or the first sign of relapsing leukemia. We here report a case of unilateral serous retinal detachment with choroidal thickening before the detection of atypical lymphocytes or myeloblasts as the initial manifestation of subsequently diagnosed acute myeloid leukemia.

Observations: A 43-year-old woman presented with serous retinal detachment in her left eye. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajoc.2019.02.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396195PMC
June 2019
1 Read

Fournier's gangrene as an initial manifestation of acute promyelocytic leukemia: A case report and review of the literature.

SAGE Open Med Case Rep 2019 1;7:2050313X19834425. Epub 2019 Mar 1.

Section of Infectious Diseases, Department of Medicine, School of Medicine, Boston University, Boston, MA, USA.

Fournier's gangrene is classically associated with diabetes mellitus and alcohol use disorder. While it is associated with chemotherapy, there are few case reports of Fournier's gangrene as the initial presentation of acute myelogenous leukemia. A 38-year-old male presented with progressive scrotal swelling and hematochezia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2050313X19834425DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399751PMC
March 2019
1 Read

Predictors of early hemorrhage in acute promyelocytic leukemia.

Leuk Lymphoma 2019 Mar 8:1-10. Epub 2019 Mar 8.

a Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai Tisch Cancer Institute , New York , NY , USA.

Fatal hemorrhage is the most common cause of induction failure and death among patients with acute promyelocytic leukemia (APL). However, there remains no established means of hemorrhagic risk stratification in APL. In this single center retrospective study of 43 patients treated for APL group-based trajectory modeling was used to identify laboratory trends associated with major bleeding. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2019.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2019.1581187DOI Listing
March 2019
3 Reads

Acute promyelocytic leukemia presenting as recurrent spinal myeloid sarcomas 3 years before developing leukemia: A case report with review of literature.

Clin Case Rep 2019 Feb 8;7(2):316-321. Epub 2019 Jan 8.

Division of Blood Transfusion Japan Red Cross Musashino Hospital Tokyo Japan.

The de novo myeloid sarcoma (MS) type of acute promyelocytic leukemia (APL) is rare, and clinical features may differ from extramedullary diseases in advanced APL. Many cases occur as a spinal tumor, and some occur in the absence of bone-marrow diseases or coagulation abnormalities. Fluorescence in situ hybridization analysis of MS tissue is useful for accurate diagnosis, even in preserved tissue. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.1991DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389481PMC
February 2019
1 Read

The combination of UCN-01 and ATRA triggers differentiation in ATRA resistant acute promyelocytic leukemia cell lines via RAF-1 independent activation of MEK/ERK.

Food Chem Toxicol 2019 Apr 3;126:303-312. Epub 2019 Mar 3.

Shanghai Institute of Hematology and State Key Laboratory of Medical Genomics, Rui-jin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Rui-jin Road II, Shanghai, 200025, China. Electronic address:

With the introduction of arsenic trioxide and all-trans retinoic acid, the prognosis of acute promyelocytic leukemia has greatly improved. However, all-trans retinoic acid resistance is still unresolved in acute promyelocytic leukemia relapsed patients. In this study, the clinical achievable concentration of 7-hydroxystaurosporine synergized with all-trans retinoic acid to induce terminal differentiation in all-trans retinoic acid resistant acute promyelocytic leukemia cell lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.fct.2019.02.033DOI Listing
April 2019
1 Read
2.895 Impact Factor

The value of FDP/FIB and D-dimer/FIB ratios in predicting high-risk APL-related thrombosis.

Leuk Res 2019 Apr 22;79:34-37. Epub 2019 Feb 22.

Department of Hematology, Zhengzhou University People's Hospital and Henan Provincial People's Hospital, #7 Weiwu Road, Zhengzhou, Henan, 450003, China. Electronic address:

Hemorrhage is the typical manifestation of APL-related coagulopathy while thrombosis is infrequently reported. In a retrospective analysis with 33 patients with hyperleukocytic APL, we found 6 out of 33 hyperleukocytic APL patients presented with thrombosis rather than hemorrhage. A notable feature in these high-risk APL patients with thrombosis is that there were no significant abnormalities in fibrinogen (FIB), prothrombin time (PT) and activated partial thromboplastin time (APTT). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126193003
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2019.02.007DOI Listing
April 2019
7 Reads

A novel flow cytometric method for enhancing acute promyelocytic leukemia screening by multidimensional dot-plots.

Ann Hematol 2019 Mar 4. Epub 2019 Mar 4.

Department of Laboratory Medicine, University of Debrecen, Nagyerdei krt. 98, Debrecen, H-4032, Hungary.

Acute promyelocytic leukemia (APL) is generally characterized by t(15;17)(q24;q21). In some cases, the classic translocation cannot be identified by conventional methods, since the PML-RARA fusion protein results from complex, variant, or cryptic translocation. The diagnostic algorithm of APL starts with screening methods, such as flow cytometry (FC), followed by fluorescence in situ hybridization or polymerase chain reaction to confirm the diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03642-wDOI Listing
March 2019
1 Read

A new pyridazinone exhibits potent cytotoxicity on human cancer cells via apoptosis and poly-ubiquitinated protein accumulation.

Cell Biol Toxicol 2019 Mar 1. Epub 2019 Mar 1.

The Cytometry, Screening, and Imaging Core Facility, Border Biomedical Research Center, Department of Biological Sciences, The University of Texas at El Paso, 500 West University Avenue, El Paso, TX, 79968-0519, USA.

In the last 15 years, pyridazinone derivatives have acquired extensive attention due to their widespread biological activities and pharmacological applications. Pyridazinones are well known for their anti-microbial, anti-viral, anti-inflammatory, anti-cancer, and cardiovascular activities, among others. In this study, we evaluated the anti-cancer activity of a new pyridazinone derivative and propose it as a potential anti-neoplastic agent in acute promyelocytic leukemia cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10565-019-09466-8DOI Listing
March 2019
1 Read

Identification of a point mutation PML-RARα that alters PML body organization, dynamics and SUMOylation.

Biochem Biophys Res Commun 2019 Feb 26. Epub 2019 Feb 26.

Department of Hematology& Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, 310003, China; Institute of Hematology, China Three Gorges University, Yichang, 443002, China. Electronic address:

Genetic mutations on PML-RARα in acute promyelocytic leukemia (APL) are reported to associate with arsenic trioxide (ATO) or all-trans retinoic acid (ATRA) resistance. Here we performed a retrospective analysis of APL patients and identified that the patient with S214L mutation on the PML moiety of PML-RARα showed resistance to both ATO and ATRA. Super-resolution microcopy was used to examine the structural response of PML bodies in wild-type or the S214L mutant cells upon drug treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2019.02.101DOI Listing
February 2019
1 Read

Functional profiling identifies determinants of arsenic trioxide cellular toxicity.

Toxicol Sci 2019 Jan 25. Epub 2019 Jan 25.

Department of Physiological Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida.

Arsenic exposure is a worldwide health concern associated with an increased risk of skin, lung and bladder cancer but arsenic trioxide (ATO; AsIII) is also an effective chemotherapeutic agent. The current use of AsIII in chemotherapy is limited to acute promyelocytic leukemia (APL). However, AsIII was suggested as a potential therapy for other cancer types including chronic myeloid leukemia (CML), especially when combined with other drugs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/toxsci/kfz024DOI Listing
January 2019
2 Reads

Fatal Intracranial Hemorrhage in a Young Pregnant Patient with Acute Promyelocytic Leukemia.

Ann Clin Lab Sci 2019 Jan;49(1):94-96

Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center at Houston McGovern Medical School, Houston, TX, USA.

Acute promyelocytic leukemia during pregnancy is associated with a high risk of fetal and obstetrical complications. Although the prognosis of acute promyelocytic leukemia is favorable due to disease-specific drugs, such as all-trans retinoic acid, early death due to fatal intracranial hemorrhage has been observed in some cases. In this study, we present a case of catastrophic intracranial hemorrhage in a young pregnant patient with the finding of leukemic involvement of the placenta. Read More

View Article

Download full-text PDF

Source
January 2019

Successful Treatment With ATRA and Arsenic Trioxide for a Child With Down Syndrome and Acute Promyelocytic Leukemia.

J Pediatr Hematol Oncol 2019 Feb 22. Epub 2019 Feb 22.

Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.

Acute promyelocytic leukemia (APL) is rare in patients with Down syndrome (DS). Cytotoxic chemotherapy combined with all-trans retinoic acid (ATRA) has been a standard treatment for APL, but is potentially intolerable for DS patients because of their vulnerability to cytotoxic agents. We report here a case of a 10-year-old girl with DS and APL successfully treated with a combination of ATRA and arsenic trioxide, a therapy emerging as a new standard for APL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000001438DOI Listing
February 2019
1 Read

Autophagy is Required to Regulate Mitochondria Renewal, Cell Attachment, and All-trans-Retinoic Acid-Induced Differentiation in NB4 Acute Promyelocytic Leukemia Cells.

J Environ Pathol Toxicol Oncol 2019 ;38(1):13-20

Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX.

All-trans-retinoic acid (ATRA) is a potent inducer of cellular differentiation, growth arrest, and apoptosis as well as a front-line therapy for acute promyelocytic leukemia (APL). The present study provides evidence that induction of autophagy is required for ATRA to induce differentiation of APL (NB4) cells into granulocytes. ATRA treatment causes ~12-fold increase in the number of acidic vesicular organelles and induces marked up-regulation of LC3-II, autophagy-related 5 (ATG5), and Beclin-1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1615/JEnvironPatholToxicolOncol.2018027885DOI Listing
January 2019
1 Read

Myeloid neoplasm with eosinophilia and PCM1-JAK2 associated with acute promyelocytic leukemia with PML-RARA.

Leuk Lymphoma 2019 Feb 26:1-5. Epub 2019 Feb 26.

c Department of Pathology and Laboratory Medicine , Hospital of the University of Pennsylvania , Philadelphia , PA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1581927DOI Listing
February 2019

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.

Blood 2019 Feb 25. Epub 2019 Feb 25.

Tor Vergata University, Rome, Italy.

Since the comprehensive recommendations for the management of APL reported in 2009, several studies have provided important insights, particularly regarding the role of ATO in frontline therapy. Ten years later, a European LeukemiaNet expert panel has reviewed the recent advances in the management of APL in both frontline and relapse settings in order to develop updated evidence- and expert opinion-based recommendations on the management of this disease. Together with providing current indications on genetic diagnosis, modern risk-adapted frontline therapy and salvage treatment, the review contains specific recommendations for the identification and management of the most important complications such as the bleeding disorder, APL differentiation syndrome, QT prolongation and other ATRA- and ATO-related toxicities, as well as for molecular assessment of the response to treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2019-01-894980DOI Listing
February 2019
2 Reads

Influence of bcr-3 PML-RARα transcript on outcome in Acute Promyelocytic Leukemia patients of Kashmir treated with all-trans retinoic acid and/or arsenic tri-oxide.

Cancer Genet 2019 Feb 29;231-232:14-21. Epub 2018 Dec 29.

Department of Education, Srinagar, J&K India.

Aims: Distinct types of PML-RARα hybrid transcripts viz bcr-1, bcr-2 and bcr-3 result from translocation between chromosomes 15 and 17 t(15;17) in Acute Promyelocytic Leukemia patients. We aimed to determine the frequencies of the PML-RARα transcripts and FLT3-ITD mutations in APL patients to evaluate their prognostic implications and also to analyze their impact on disease outcome.

Main Method: RT-PCR and Rq-PCR were adopted for transcript typing and quantitation of PML-RARα transcripts while FLT3-ITD was detected by PCR in APL patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cancergen.2018.12.003DOI Listing
February 2019
1 Read

Acute Myeloid Leukemia with Occult Systemic Mastocytosis or Atypical Mast Cells Post-induction.

Cureus 2018 Dec 14;10(12):e3734. Epub 2018 Dec 14.

Oncology, Jinnah Postgraduate Medical Centre, Karachi, PAK.

Systemic mastocytosis (SM) is a state of disease that is related to the clonal, neoplastic proliferation of mast cells. Patients who present with SM-Acute Myeloid Leukemia (AML) often have the worst outcome. We present a case of an 18-year-old female who was diagnosed with AML (FLT3 (Fms like tyrosine kinase 3) and PML-RARA (promyelocytic leukemia-retinoic acid receptor alpha) translocation-negative) and after initial treatment with a standard induction regimen of cytarabine and daunorubicin (3+7 regimen), her bone marrow showed blast cells less than 5% and dense aggregates/sheets of atypical/immature mast cells with immunohistochemical stain CD117+ve and toluidine blue positive in mast cell aggregates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.3734DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384037PMC
December 2018
2 Reads

Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide.

Expert Rev Clin Pharmacol 2019 Feb 22:1-8. Epub 2019 Feb 22.

b Department of Hematology , The First Affiliated Hospital of Harbin Medical University , Harbin , China.

Background: Arsenic trioxide (ATO) is widely applied to treat acute promyelocytic leukemia (APL). To elucidate metabolism and toxicity of arsenic, we analyzed time course of arsenic species in red blood cells (RBCs) of APL patients.

Methods: Nine APL patients received ATO (0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1586532DOI Listing
February 2019

Strategies to inhibit arsenic trioxide-induced cardiotoxicity in acute promyelocytic leukemia.

J Cell Physiol 2019 Feb 15. Epub 2019 Feb 15.

Thalassemia and Hemoglobinopathy Research Center, Research Institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Objective: Arsenic trioxide (ATO) is a drug commonly used for the treatment of acute promyelocytic leukemia (APL). Although ATO has been shown to cause significant improvement in patients, it is associated with serious side effects, which sometimes lead to the patient's death. In this review paper, we examine the reports of ATO-induced cardiotoxicity in APL patients and evaluate the strategies to reduce the incidence of such toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.28292DOI Listing
February 2019
1 Read

Toward Candidate Proteomic Biomarkers in Clinical Monitoring of Acute Promyelocytic Leukemia Treatment with Arsenic Trioxide.

OMICS 2019 Feb;23(2):119-130

2 School of Medical and Health Sciences, Edith Cowan University, Perth, Australia.

The introduction of arsenic trioxide (ATO) in treatment of acute promyelocytic leukemia (APL) has resulted in high clinical complete remission (CR) rates over 90%. On the contrary, the risk for early death (ED) in APL patients treated with ATO continues to have a negative impact for optimization of APL therapeutics. There is an urgent need for precision medicine and biomarkers in clinical monitoring of ATO toxicity in APL, and ED in particular. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/omi.2018.0178DOI Listing
February 2019
1 Read

SHP1 and SHP2 inhibition enhances the pro-differentiative effect of phorbol esters: an alternative approach against acute myeloid leukemia.

J Exp Clin Cancer Res 2019 Feb 14;38(1):80. Epub 2019 Feb 14.

Department of Biochemistry and Molecular Biology, University of Salamanca, Edificio Departamental, Lab 122, Plaza Doctores de la Reina, S/N, P.O. 37007, Salamanca, Spain.

Background: The differentiation-based therapy for acute promyelocytic leukemia (APL) is an inspiring example for the search of novel strategies aimed at treatment of other subtypes of acute myeloid leukemia (AML). Thus, the discovery of new molecular players in cell differentiation becomes a paramount research area to achieve this goal. Here, the involvement of the protein tyrosine phosphatases SHP1 and SHP2 on leukemic cells differentiation is shown, along with the therapeutic possibilities of their targeting to enhance the differentiation induction effect of phorbol esters. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-019-1097-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376690PMC
February 2019
1 Read

Analysis of the role of thrombomodulin in all-trans retinoic acid treatment of coagulation disorders in cancer patients.

Theor Biol Med Model 2019 02 14;16(1). Epub 2019 Feb 14.

Department of Mechanical Engineering, University of California Santa Barbara, Santa Barbara, CA, 93106, USA.

Background: Clinical studies have shown that all-trans retinoic acid (RA), which is often used in treatment of cancer patients, improves hemostatic parameters and bleeding complications such as disseminated intravascular coagulation (DIC). However, the mechanisms underlying this improvement have yet to be elucidated. In vitro studies have reported that RA upregulates thrombomodulin (TM) expression on the endothelial cell surface. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12976-019-0099-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376718PMC
February 2019

Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells.

Exp Cell Res 2019 Mar 11;376(2):114-123. Epub 2019 Feb 11.

Central Laboratory, The Union Hospital of Fujian Medical University, Fuzhou, China. Electronic address:

Relapse of minimal residual disease (MRD) is a major problem after conventional chemotherapy in patients with acute myeloid leukemia (AML). The bone marrow stroma can protect AML cells from insults of chemotherapy, partly contributing to AML relapse. Arsenic trioxide (ATO) is the main component of arsenical traditional Chinese medicines and has been widely used for the treatment of hematologic malignancies particularly acute promyelocytic leukemia over the past three decades. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexcr.2019.02.008DOI Listing
March 2019
1 Read

A candidate for lung cancer treatment: arsenic trioxide.

Authors:
W Huang Y C Zeng

Clin Transl Oncol 2019 Feb 12. Epub 2019 Feb 12.

Department of Medical Oncology, Shengjing Hospital of China Medical University, 39 Huaxiang Road, Shenyang, 110022, China.

Arsenic trioxide (ATO), a highly effective drug in treating acute promyelocytic leukemia with low toxicity, demonstrates a significant effect on lung cancer. The anti-cancer mechanisms of ATO include inhibition of cancer stem-like cells, induction of apoptosis, anti-angiogenesis, sensitization of chemotherapy and radiotherapy, anti-cancer effects of hypoxia, and immunoregulation properties. In addition, some studies have reported that different lung cancers respond differently to ATO. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12094-019-02054-6DOI Listing
February 2019
1 Read

A Pilot Study of Aberrant CpG Island Hypermethylation of in Acute Myeloloid Leukemia.

Int J Med Sci 2019 1;16(2):324-330. Epub 2019 Jan 1.

Department of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning Province, 110001, China.

Epigenetic silencing of tumor suppressor genes plays important role in acute myeloid leukemia (AML). Recently, SPRED1, a negative regulator of the RAS MAPK pathway, is identified as a tumour suppressor downregulated in AML. However, little is known regarding its underlying dysregulation in AML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/ijms.27757DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367533PMC
January 2019
1 Read
2.003 Impact Factor

The Cardiotoxicity Induced by Arsenic Trioxide is Alleviated by Salvianolic Acid A via Maintaining Calcium Homeostasis and Inhibiting Endoplasmic Reticulum Stress.

Molecules 2019 Feb 2;24(3). Epub 2019 Feb 2.

Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100193, China.

Arsenic trioxide (ATO) has been verified as a breakthrough with respect to the management of acute promyelocytic leukemia (APL) in recent decades but associated with some serious adverse phenomena, particularly cardiac functional abnormalities. Salvianolic acid A (Sal A) is a major effective component in treating ATO-induced cardiotoxicity. Therefore, the objective of our study was to assess whether Sal A had protective effects by the regulation of calcium homeostasis and endoplasmic reticulum (ER) stress. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/molecules24030543DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384753PMC
February 2019
1 Read

Comparing the epidemiology, clinical characteristics and prognostic factors of acute myeloid leukemia with and without acute promyelocytic leukemia.

Carcinogenesis 2019 Jan 23. Epub 2019 Jan 23.

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Acute promyelocytic leukemia (APL) is a particularly aggressive subtype of acute myeloid leukemia (AML), with high rates of early death. It is important to examine how epidemiologic characteristics, clinical and treatment factors, cytogenetic and genetic data affect survival and differ between APL and non-APL AML patients. We analyzed population data from the New York State Cancer Registry to characterize AML including APL incidence rates by demographics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgz014DOI Listing
January 2019
3 Reads

FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients.

Bone Marrow Transplant 2019 Feb 1. Epub 2019 Feb 1.

Peking University People's Hospital, Peking University Institute of Hematology, Beijing, P.R. China.

Acute myelogenous leukemia (AML) patients with fetal liver tyrosine kinase 3 (FLT3) internal tandem duplications (ITDs) have poor prognoses if treated with chemotherapy only, primarily as they experience increased relapse rates. To determine whether this alteration also affects outcomes after haploidentical donor (HID) allogeneic hematopoietic stem cell transplantation (allo-HSCT), we compared 334 consecutive FLT3-ITD-positive vs -negative patients with AML (other than acute promyelocytic leukemia) who underwent HID-HSCT. FLT3-ITD was detected in 39 of 334 patients (11. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0456-xDOI Listing
February 2019
3 Reads

Tetra-arsenic tetra-sulfide ameliorates lupus syndromes by inhibiting IL-17 producing double negative T cells.

Dermatol Ther 2019 Feb 1:e12849. Epub 2019 Feb 1.

Department of Dermatology, People's Hospital of Peking University, Beijing, China.

Systemic lupus erythematosus (SLE) is an autoimmune disease of uncertain etiology that affects multiple tissues and organs. Tetra-arsenic tetra-sulfide (As S ), a traditional Chinese medicine, is effective on acute promyelocytic leukemia with mild side effects. In our previous study, BXSB lupus-prone mice treated with As S has showed improved monocytosis, decreased serum interleukin (IL)-6 and suppressed skin, liver and renal lesions with well-tolerance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12849DOI Listing
February 2019
2 Reads

Molecular profiling of adult acute myeloid and lymphoid leukemia in a major referral center in Lebanon: a 10-year experience report and review of the literature.

Mol Biol Rep 2019 Jan 30. Epub 2019 Jan 30.

Molecular Diagnostics Laboratory, Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, PO BOX 11-0236, Beirut, Lebanon.

Recurrent genetic abnormalities confer distinct morphologic features and play a role in determining the clinical behavior, prognosis and adequate treatment of acute leukemia. In the MENA region, only one study targets the frequency of genetic modifications in AML, reporting a higher occurrence of acute promyelocytic leukemia in Lebanon. Determining the frequency of translocations and gene mutations in acute myeloid and lymphoid leukemia cases in an adult patients' population in Lebanon and comparing the resultant genetic profile with the published international molecular profile of adult acute leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11033-019-04649-2DOI Listing
January 2019
2 Reads
2.024 Impact Factor

[Involvement of PML proteins in treatment of acute promyelocytic leukemia with arsenic trioxide].

Zhejiang Da Xue Xue Bao Yi Xue Ban 2018 May;47(5):541-551

Department of Pharmacology, Inner Mongolia Medical University, Hohhot 010000, China.

Promyelocytic leukemia (PML) protein, a tumor suppressor, plays an important role in patients with acute promyelocytic leukemia (APL) receiving arsenic trioxide (AsO) therapy. APL is a M3 subtype of acute myeloid leukemia (AML), which is characterized by expression of PML-RARα (P/R) fusion protein, leading to the oncogenesis. AsO is currently used as the first-line drug for patients with APL, and the mechanism may be:AsO directly binds to PML part of P/R protein and induces multimerization of related proteins, which further recruits different functional proteins to reform PML nuclear bodies (PML-NBs), and finally it degraded by SUMOylation and ubiquitination proteasomal pathway. Read More

View Article

Download full-text PDF

Source
May 2018
1 Read

A complex translocation (1;17;15) with spliced short-type PML-RARA fusion transcripts in acute promyelocytic leukemia: A case report.

Exp Ther Med 2019 Feb 13;17(2):1360-1366. Epub 2018 Dec 13.

Jilin Provincial Key Laboratory on Molecular and Chemical Genetics, The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China.

The promyelocytic leukemia (PML)-retinoic acid receptor α (RARA) fusion is hypothesized to serve a vital role in the pathogenesis of acute promyelocytic leukemia (APL), which results from a reciprocal translocation between chromosomes 15 and 17, t(15;17)(q24;q21). A minority of APL cases lack the classical t(15;17) and have been identified to have cryptic or masked t(15;17) or complex translocations. The present study reports on a case of a 37-year-old male with APL harboring a complex three-way translocation t(1;17;15)(q21;q21;q24). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2018.7091DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327484PMC
February 2019
1 Read

Effect of continuous venovenous haemodialysis on outcome and pharmacokinetics of arsenic species in a patient with acute promyelocytic leukaemia and acute kidney injury.

Br J Clin Pharmacol 2019 Apr 14;85(4):849-853. Epub 2019 Feb 14.

Department of Pharmacy, the First Hospital, Harbin Medical University, 23 Youzheng Street, Nangang District, Harbin, 150001, China.

This study presents outcome and pharmacokinetics of arsenic trioxide (ATO) metabolites in patients on continuous venovenous haemodialysis (CVVHD). Of 3 acute promyelocytic leukaemia patients receiving CVVHD in management of acute kidney injury, only 1 patient was included. The patient presented disseminated intravascular coagulation and acute kidney injury before induction therapy was conducted. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bcp.13875
Publisher Site
http://dx.doi.org/10.1111/bcp.13875DOI Listing
April 2019
25 Reads

Lung resistance-related protein (LRP) predicts favorable therapeutic outcome in Acute Myeloid Leukemia.

Sci Rep 2019 Jan 23;9(1):378. Epub 2019 Jan 23.

Jinnah Medical and Dental College, Karachi, Pakistan.

There is conflicting evidence that MDR1, MRP2 and LRP expression is responsible for chemotherapy resistance. We conducted this study to explore their role in AML therapy outcomes. Bone marrow and peripheral blood samples of 90 AML patients, receiving chemotherapy, were analyzed by real time PCR. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41598-018-36780-8
Publisher Site
http://dx.doi.org/10.1038/s41598-018-36780-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344578PMC
January 2019
7 Reads

FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias.

Blood 2019 Jan 23. Epub 2019 Jan 23.

Service de Biochimie, AP-HP, Hopital St Louis, Paris, France

Acute promyelocytic leukemia (APL) is often associated with activating FLT3 signaling mutations. These are highly related to hyperleukocytosis, a major adverse risk factor with chemotherapy-based regimens. APL is a model for oncogene-targeted therapies: all-trans retinoic acid (ATRA) and arsenic both target and degrade its PML/RARA driver. Read More

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-07
Publisher Site
http://dx.doi.org/10.1182/blood-2018-07-866095DOI Listing
January 2019
9 Reads

Flexural Eruption Associated With Arsenic Trioxide Therapy in a Patient With Acute Promyelocytic Leukemia.

JAMA Dermatol 2019 Jan 23. Epub 2019 Jan 23.

Department of Dermatology, University of Virginia Health System, Charlottesville.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2018.5258DOI Listing
January 2019

Approaches for generation of anti-leukemia specific T cells.

Cell Regen (Lond) 2018 Dec 2;7(2):40-44. Epub 2018 Nov 2.

Key Laboratory for Regenerative Medicine of Ministry of Education; Institute of Hematology, School of Medicine; Jinan University, Guangzhou, 510632, China.

As three decades ago, it was reported that adoptive T cell immunotherapy by infusion of autologous tumor infiltrating lymphocytes (TILs) mediated objective cancer regression in patients with metastatic melanoma. A new era of T cell immunotherapy arose since the improvement and clinical use of anti-CD19 chimeric antigen receptor T cells (CAR-T) for the treatment of refractory and relapsed B lymphocyte leukemia. However, several challenges and difficulties remain on the way to reach generic and effective T cell immunotherapy, including lacking a generic method for generating anti-leukemia-specific T cells from every patient. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S20459769183001
Publisher Site
http://dx.doi.org/10.1016/j.cr.2018.09.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326242PMC
December 2018
10 Reads

Oral Manifestation as the Main Sign of an Advanced Stage Acute Promyelocytic Leukemia.

Acta Stomatol Croat 2018 Dec;52(4):358-362

Departamento de Medicina Oral e Odontologia Infantil. Universidade Estadual de Londrina. Rua Pernambuco 540, Londrina-PR. Brasil.

Acute myeloid leukemia is an aggressive malignant neoplasm occurring mainly in elderly, with the median age of 65 years. Oral manifestations, mainly spontaneous bleeding, are a common finding in acute myelocytic leukemia and may represent the initial evidence of the disease. This report describes a case of a 47-year-old man with a one-month history of spontaneous oral bleeding. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15644/asc52/4/10DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336446PMC
December 2018
1 Read

An Unusual Coexistence of Primary Central Nervous System Non-Hodgkin's Lymphoma and Acute Promyelocytic Leukemia.

Case Rep Hematol 2018 19;2018:2741939. Epub 2018 Dec 19.

Nicola Stefano Fracchiolla, Mariarita Sciumè, Agostino Cortelezzi, Hematology Unit, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122 Milan, Italy.

Acute promyelocytic leukemia and primary central nervous system lymphoma are uncommon hematological malignancies. The co-occurrence of acute myeloid leukemia with various lymphoproliferative diseases is an extremely rare condition, especially in the absence of previous chemotherapy or radiotherapy. Herein, we provide a comprehensive characterization of a patient with concomitant diagnosis of extranodal high-grade non-Hodgkin B-cell neoplasm confined to the central nervous system and acute promyelocytic leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/2741939DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313991PMC
December 2018
2 Reads

Factors Affecting Early Death and Survival of Patients With Acute Promyelocytic Leukemia Treated With ATRA-Based Therapy Regimens.

Clin Lymphoma Myeloma Leuk 2019 Jan 11;19(1):e63-e70. Epub 2018 Aug 11.

Senior Department of Haematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China. Electronic address:

Purpose: To perform a retrospective analysis of the prognostic relevance of clinicopathologic parameters in a well-documented cohort of patients treated with all-trans-retinoic acid (ATRA)-based induction regimens in order to discover which indicators can predict a high risk of early death (ED) and patient survival.

Patients And Methods: We analyzed data of 288 newly diagnosed adult acute promyelocytic leukemia patients in Hangzhou, China. The median follow-up time was 32 months (range, 6-78 months). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.08.001DOI Listing
January 2019
3 Reads

Contributory role of microRNAs in anti-cancer effects of small molecule inhibitor of telomerase (BIBR1532) on acute promyelocytic leukemia cell line.

Eur J Pharmacol 2019 Mar 15;846:49-62. Epub 2019 Jan 15.

Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address:

Telomerase-mediated immortalization and proliferation of tumor cells is a promising anti-cancer treatment strategy and development of potent telomerase inhibitors is believed to open new window of treatments in human malignancies. In the present study, we found that BIBR1532, a small molecule inhibitor of human telomerase, exerted cytotoxic effects on a panel of human cancer cells spanning from solid tumors to hematologic malignancies; however, as compared with solid tumors, leukemic cells were more sensitive to this inhibitor. This was independent of molecular status of p53 in the leukemic cells. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00142999193002
Publisher Site
http://dx.doi.org/10.1016/j.ejphar.2019.01.018DOI Listing
March 2019
9 Reads

Targeted arsenite-loaded magnetic multifunctional nanoparticles for treatment of hepatocellular carcinoma.

Nanotechnology 2019 Jan 17;30(17):175101. Epub 2019 Jan 17.

Fujian Provincial Key Laboratory of Chronic Liver Disease and Hepatocellular Carcinoma, Xiamen Translational Medical Key Laboratory of Hepatobiliary and Pancreatic Tumor, Zhongshan Hospital, Xiamen University, Xiamen 361004, People's Republic of China.

Arsenic trioxide (ATO), an FDA-approved drug for acute promyelocytic leukemia, also has great potential for treatment of solid tumors. Drug delivery powered by recent advances in nanotechnology has boosted the efficacy of many drugs, which is enlightening for applications of ATO in treating solid tumors. Herein, we reported arsenite-loaded multifunctional nanoparticles that are capable of pH-responsive ATO release for treating hepatocellular carcinoma (HCC) and real-time monitoring via magnetic resonance imaging. Read More

View Article

Download full-text PDF

Source
http://iopscience.iop.org/article/10.1088/1361-6528/aaff9e
Publisher Site
http://dx.doi.org/10.1088/1361-6528/aaff9eDOI Listing
January 2019
9 Reads

Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse.

Proteomics Clin Appl 2019 Jan 16:e1800133. Epub 2019 Jan 16.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030-4009, USA.

Purpose: Acute promyelocytic leukemia (APL) is the most prognostically favorable subtype of Acute myeloid leukemia (AML). Defining the features that allow identification of APL patients likely to relapse after therapy remains challenging.

Experimental Design: Proteomic profiling is performed on 20 newly diagnosed APL, 205 non-APL AML, and 10 normal CD34+ samples using Reverse Phase Protein Arrays probed with 230 antibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/prca.201800133DOI Listing
January 2019
6 Reads